An Audit of the Use of Cabazitaxel for the Treatment of Metastatic Castrate Resistant Prostate Cancer (mCRPC) Compared with Previous Experience with ECarboF (Epirubicin, Carboplatin and 5-fluorouracil) in a Single Institution. Issue 5 (May 2016) - Al-Bakir, M.; Williams, S.; Davda, R.; Mascoll, J.; Lynch, C.; Mitra, A.; Payne, H.; Dickson, J.; Harland, S.; Lopes, A.; McGovern, U.; Chau, N.-M.; et al.